Suicide gene therapy for urogenital cancer: Current outcome and prospects

Yasutomo Nasu, N. Kusaka, T. Saika, T. Tsushima, H. Kumon

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Viral-mediated transfer of the herpes simplex virus thymidine kinase (HSV-tk) gene has been demonstrated by several investigators to confer sensitivity to nucleoside analogs such as ganciclovir (GCV) in a variety of tumor cells including brain, prostate, bladder, kidney, ovary, head and neck, lung, pancreas, and liver cancers. Fourteen suicide gene clinical protocols using adenovirus vectors have been conducted, including four in prostate cancer. Two additional protocols for prostate cancer are in preparation in Japan and the Netherlands. A study conducted at Baylor College of Medicine was the first to demonstrate the safety of HSV-tk plus GCV therapy for human prostate cancer and the anticancer activity of gene therapy in this disease. However, it is still in the early stage of its development, with a number of problems to be overcome. Systemic delivery, specific introduction, and specific expression of the target gene are the major issues to be managed in order to establish a clinically relevant treatment strategy.

Original languageEnglish
Pages (from-to)67-71
Number of pages5
JournalMolecular Urology
Volume4
Issue number2
Publication statusPublished - 2000

Fingerprint

Urogenital Neoplasms
Genetic Therapy
Suicide
Prostatic Neoplasms
Ganciclovir
Thymidine Kinase
Simplexvirus
Liver Neoplasms
Head and Neck Neoplasms
Clinical Protocols
Pancreatic Neoplasms
Nucleosides
Adenoviridae
Netherlands
Genes
Prostate
Ovary
Lung Neoplasms
Japan
Urinary Bladder

ASJC Scopus subject areas

  • Urology

Cite this

Nasu, Y., Kusaka, N., Saika, T., Tsushima, T., & Kumon, H. (2000). Suicide gene therapy for urogenital cancer: Current outcome and prospects. Molecular Urology, 4(2), 67-71.

Suicide gene therapy for urogenital cancer : Current outcome and prospects. / Nasu, Yasutomo; Kusaka, N.; Saika, T.; Tsushima, T.; Kumon, H.

In: Molecular Urology, Vol. 4, No. 2, 2000, p. 67-71.

Research output: Contribution to journalArticle

Nasu, Y, Kusaka, N, Saika, T, Tsushima, T & Kumon, H 2000, 'Suicide gene therapy for urogenital cancer: Current outcome and prospects', Molecular Urology, vol. 4, no. 2, pp. 67-71.
Nasu, Yasutomo ; Kusaka, N. ; Saika, T. ; Tsushima, T. ; Kumon, H. / Suicide gene therapy for urogenital cancer : Current outcome and prospects. In: Molecular Urology. 2000 ; Vol. 4, No. 2. pp. 67-71.
@article{ab503d471bc14a1c95bc949c8f3b8297,
title = "Suicide gene therapy for urogenital cancer: Current outcome and prospects",
abstract = "Viral-mediated transfer of the herpes simplex virus thymidine kinase (HSV-tk) gene has been demonstrated by several investigators to confer sensitivity to nucleoside analogs such as ganciclovir (GCV) in a variety of tumor cells including brain, prostate, bladder, kidney, ovary, head and neck, lung, pancreas, and liver cancers. Fourteen suicide gene clinical protocols using adenovirus vectors have been conducted, including four in prostate cancer. Two additional protocols for prostate cancer are in preparation in Japan and the Netherlands. A study conducted at Baylor College of Medicine was the first to demonstrate the safety of HSV-tk plus GCV therapy for human prostate cancer and the anticancer activity of gene therapy in this disease. However, it is still in the early stage of its development, with a number of problems to be overcome. Systemic delivery, specific introduction, and specific expression of the target gene are the major issues to be managed in order to establish a clinically relevant treatment strategy.",
author = "Yasutomo Nasu and N. Kusaka and T. Saika and T. Tsushima and H. Kumon",
year = "2000",
language = "English",
volume = "4",
pages = "67--71",
journal = "Molecular Urology",
issn = "1091-5362",
publisher = "Mary Ann Liebert Inc.",
number = "2",

}

TY - JOUR

T1 - Suicide gene therapy for urogenital cancer

T2 - Current outcome and prospects

AU - Nasu, Yasutomo

AU - Kusaka, N.

AU - Saika, T.

AU - Tsushima, T.

AU - Kumon, H.

PY - 2000

Y1 - 2000

N2 - Viral-mediated transfer of the herpes simplex virus thymidine kinase (HSV-tk) gene has been demonstrated by several investigators to confer sensitivity to nucleoside analogs such as ganciclovir (GCV) in a variety of tumor cells including brain, prostate, bladder, kidney, ovary, head and neck, lung, pancreas, and liver cancers. Fourteen suicide gene clinical protocols using adenovirus vectors have been conducted, including four in prostate cancer. Two additional protocols for prostate cancer are in preparation in Japan and the Netherlands. A study conducted at Baylor College of Medicine was the first to demonstrate the safety of HSV-tk plus GCV therapy for human prostate cancer and the anticancer activity of gene therapy in this disease. However, it is still in the early stage of its development, with a number of problems to be overcome. Systemic delivery, specific introduction, and specific expression of the target gene are the major issues to be managed in order to establish a clinically relevant treatment strategy.

AB - Viral-mediated transfer of the herpes simplex virus thymidine kinase (HSV-tk) gene has been demonstrated by several investigators to confer sensitivity to nucleoside analogs such as ganciclovir (GCV) in a variety of tumor cells including brain, prostate, bladder, kidney, ovary, head and neck, lung, pancreas, and liver cancers. Fourteen suicide gene clinical protocols using adenovirus vectors have been conducted, including four in prostate cancer. Two additional protocols for prostate cancer are in preparation in Japan and the Netherlands. A study conducted at Baylor College of Medicine was the first to demonstrate the safety of HSV-tk plus GCV therapy for human prostate cancer and the anticancer activity of gene therapy in this disease. However, it is still in the early stage of its development, with a number of problems to be overcome. Systemic delivery, specific introduction, and specific expression of the target gene are the major issues to be managed in order to establish a clinically relevant treatment strategy.

UR - http://www.scopus.com/inward/record.url?scp=0034095809&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034095809&partnerID=8YFLogxK

M3 - Article

C2 - 12006245

AN - SCOPUS:0034095809

VL - 4

SP - 67

EP - 71

JO - Molecular Urology

JF - Molecular Urology

SN - 1091-5362

IS - 2

ER -